検査と技術51巻9号

2023年09月発行

増大号 匠から学ぶ　血栓止血検査ガイド 5章　疾患まとめ

深部静脈血栓症（DVT）／肺血栓塞栓症（PE）

著者： 荻原義人¹ 土肥薫¹ 伊藤正明¹

所属機関： ¹三重大学医学部附属病院循環器内科

ページ範囲：P.1111 - P.1115

疾患概念

　肺血栓塞栓症（pulmonary thromboembolism：PTEまたはPE，本稿ではPEを用いる．なお，本稿でのPEは急性PEを指す）と深部静脈血栓症（deep vein thrombosis：DVT）は一連の病態と考えられており，まとめて静脈血栓塞栓症（venous thromboembolism：VTE）と呼ばれる．

　四肢の筋膜より深層を走行する深部静脈に発生した血栓症をDVTと呼び，それより中枢側に位置する腸骨静脈，下大静脈，鎖骨下静脈，腕頭静脈，上大静脈，さらに内頸静脈に発生した血栓症もDVTに含まれる．静脈血栓が遊離し，塞栓子として肺動脈を閉塞した結果，PEを発症する．PEの塞栓源の約90％は下肢あるいは骨盤内の静脈由来とされる^1）．

参考文献

1）日本循環器学会，他．肺血栓塞栓症および深部静脈血栓症の診断，治療，予防に関するガイドライン（2017年改訂版）．2017．　https://js-phlebology.jp/wp/wp-content/uploads/2020/08/JCS2017.pdf（2023年6月21日アクセス）

2）Heit JA, et al. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016; 41: 3-14.

3）Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023; 20: 248-262.

4）Nakamura M, et al. Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy. J Cardiol. 2015; 66: 451-459.

5）Kuroiwa M, et al. Changes in the incidence, case fatality rate, and characteristics of symptomatic perioperative pulmonary thromboembolism in Japan: Results of the 2002-2011 Japanese Society of Anesthesiologists Perioperative Pulmonary Thromboembolism (JSA-PTE) Study. J Anesth. 2015; 29: 433-441.

6）Ota S, et al. Incidence, Characteristics and Management of Venous Thromboembolism in Japan During 2011. Circ J. 2018; 82: 555-560.

7）Nakamura M, et al. Current venous thromboembolism management and outcomes in Japan. Circ J. 2014; 78: 708-717.

8）Yamashita Y, et al. Anticoagulation Therapy for Venous Thromboembolism in the Real World - From the COMMAND VTE Registry. Circ J. 2018; 82: 1262-1270.

9）Carson JL, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992; 326: 1240-1245.

10）Yamashita Y, et al. Validation of simplified PESI score for identification of low-risk patients with pulmonary embolism: From the COMMAND VTE Registry. Eur Heart J Acute Cardiovasc Care. 2020; 9: 262-270.

11）Stark, K et al. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021; 18: 666-682.

12）Stein PD, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med. 2004; 140: 589-602.

13）Konstantinides SV, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020; 41: 543-603.

14）Johnson ED, et al. The D-dimer assay. Am J Hematol. 2019; 94: 833-839.

15）Palareti G, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006; 355: 1780-1789.

16）Douketis J, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010; 153: 523-531.

17）Cosmi B, et al. Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. J Thromb Haemost. 2010; 8: 1933-1942.

18）Wada H, et al. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost. 2006; 4: 1253-1258.

19）Cosmi B, et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG Ⅱ prospective study. Blood 2010; 115: 481-488.